SGCG and hereditary thrombophilia due to congenital protein S deficiency: Recent preclinical studies in mice have also shown promise for using AAV-based gene transfer therapy to treat LGMD type 2C/R5, which is caused by mutations in the gamma sarcoglycan gene (SGCG) that lead to protein deficiency [98].